Filing Flows › Companies › Halozyme Therapeutics › Timeline
Halozyme Therapeutics stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+51.5% to $103.63
Halozyme Therapeutics (HALO) stock rose 51% over the last 252 sessions, to $103.63. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 5 Form 144 notices of planned sales, and the company filed 10 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 1.5% | −5.8% (−1.3% vs SPY) | — | — |
| Sep 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.2% (−3.4% vs SPY) | +0.3% (−1.5% vs SPY) | +17.2% (+16.4% vs SPY) |
| Sep 22, 2026 | 8-K | Material definitive agreement | −2.4% (−1.6% vs SPY) | −3.1% (−2.0% vs SPY) | +8.1% (+8.1% vs SPY) |
| Sep 16, 2026 | Form 144 | Form 144: Matthew Posard plans to sell $3.6M | +2.0% (+2.5% vs SPY) | +8.0% (+5.7% vs SPY) | +9.5% (+7.6% vs SPY) |
| Aug 18, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.6% (+2.4% vs SPY) | +4.1% (+4.3% vs SPY) | +4.5% (+5.1% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Helen Torley plans to sell $23.7M | +4.3% (+4.8% vs SPY) | +9.2% (+10.6% vs SPY) | +7.4% (+9.9% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Cortney A Caudill plans to sell $4.3M | 0.0% (+0.3% vs SPY) | +0.4% (+0.4% vs SPY) | +4.5% (+5.9% vs SPY) |
| Aug 10, 2026 | Form 144 | Form 144: Bernadette Connaughton plans to sell $168K | −0.5% (−0.5% vs SPY) | −4.4% (−4.8% vs SPY) | +4.9% (+5.8% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 25.5% | +2.6% (+2.7% vs SPY) | +19.7% (+19.3% vs SPY) | +28.1% (+27.7% vs SPY) |
| Jul 2, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.7% (+0.8% vs SPY) | −4.2% (−5.5% vs SPY) | +3.5% (+1.8% vs SPY) |
| Jun 29, 2026 | Form 144 | Form 144: Mahesh Krishnan plans to sell $548K | +2.9% (+1.3% vs SPY) | +7.5% (+4.5% vs SPY) | +10.7% (+9.1% vs SPY) |
| May 11, 2026 | Earnings | Earnings: beat the EPS estimate by 5.3% | +3.5% (+3.3% vs SPY) | +4.6% (+4.3% vs SPY) | +10.8% (+10.9% vs SPY) |
| Apr 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.0% (0.0% vs SPY) | +5.1% (+2.0% vs SPY) | +5.4% (−0.7% vs SPY) |
| Mar 12, 2026 | 8-K | Directors and officers: departures, appointments, pay | −4.5% (−3.0% vs SPY) | −4.4% (−2.1% vs SPY) | +2.0% (+1.3% vs SPY) |
| Feb 17, 2026 | Earnings | Earnings: missed the EPS estimate by -110.9% | +1.3% (+1.1% vs SPY) | −11.7% (−11.8% vs SPY) | −19.9% (−18.2% vs SPY) |
| Dec 9, 2025 | 8-K | Directors and officers: departures, appointments, pay | +1.3% (+0.6% vs SPY) | +4.1% (+4.7% vs SPY) | +15.8% (+13.9% vs SPY) |
| Dec 8, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.6% (−1.5% vs SPY) | +0.9% (+1.3% vs SPY) | +13.7% (+12.6% vs SPY) |
| Nov 24, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.6% (−2.5% vs SPY) | −10.6% (−12.5% vs SPY) | −7.9% (−11.4% vs SPY) |
| Nov 12, 2025 | 8-K | Material definitive agreement | +0.8% (+2.5% vs SPY) | −0.5% (+2.5% vs SPY) | −12.7% (−12.5% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Halozyme Therapeutics: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.